Benefits of ninerafaxstat in non-obstructive hypertrophic cardiomyopathy

Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01032-yAccording to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited.

https://www.nature.com/articles/s41569-024-01032-y

Source: Nature Reviews Cardiology - April 23, 2024 Category: Cardiology Authors: Gregory B. Lim Source Type: research

More News: Cardiology | Cardiomyopathy | Heart | Hypertrophic Cardiomyopathy | Sports Medicine